by Raynovich Rod | Jan 23, 2014 | Biopharmaceuticals
Update 1/24 With 2 hrs Trading to go…..Technical levels holding with sector up 7-8% YTD. NASDAQ still falling down 1.9% at 4139, QQQ down 1.5% Given the huge 11% move through the J.P.Morgan Conference in January we should only look at technical levels until...
by Raynovich Rod | Jan 21, 2014 | Biopharmaceuticals, Clinical Diagnostics and Tools
Life Science Stocks Moving Again-XBI up 1.54% After a 15%+ move January YTD you would think it is time to step back and take some off. Today the rally was in a full bull MOde with biopharmaceutical stocks leading the way. Here are big upside movers among our focus...
by Raynovich Rod | Jan 20, 2014 | 2024 Rayno Tools and Diagnostics Portfolio, Clinical Diagnostics and Tools
2014 J.P. Morgan Conference Update #5-Rayno Diagnostics and Tools Portfolio Amazing start for the New Year Performance among Clinical Diagnostics and Tools stocks was strong with many stocks beating the sector indices (IBB) which were up 10-15%. Stock performance...
by Raynovich Rod | Dec 30, 2013 | 2024 Rayno Tools and Diagnostics Portfolio
New Products for Molecular and Companion Diagnostics Drive Growth Rayno Life Science Big Winners-ALR, CSII, ILMN,TMO A diversified life science portfolio must include clinical diagnostics and tools stocks because of the synergies between therapy and diagnostics....
by Rod Raynovich | Oct 15, 2010 | BIOgraph
The Rayno Life Science Portfolio is up 20% and later this month we will see important earnings reports from tools and diagnostics companies. Life Science stocks are outperforming the NASDAQ and S&P in 2010. Exact Sciences(EXAS) $8.89 was a high flier for Q3 with...
by Rod Raynovich | Jan 15, 2009 | Biopharmaceuticals, Clinical Diagnostics and Tools
JPMorgan Healthcare Conference Monday briefing: Rod Raynovich Webcast at: https://events.jpmorgan.com Biotech Valuations at trough levels About 4000 attendees consisting of mutual and hedge fund investors,VC’s, Company executives and their PR legions registered the...